Disclosing the results of clinical trials: how is the pharmaceutical industry doing?

2018 ◽  
Author(s):  
Antonia Panayi ◽  
◽  
Slavka Baronikova ◽  
Jim Purvis ◽  
Eric Southam ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pharmaceutical Industry

On Innovative Activity in Pharmaceutical Industry

Vestnik NSUEM ◽  
2021 ◽  
pp. 168-174
Author(s):  
M. I. Berkovich ◽  
A. Yu. Volin
Keyword(s):  
Clinical Trials ◽  
Pharmaceutical Industry ◽  
Clustering Algorithm ◽  
Innovative Activity ◽  
Innovation Activity ◽  
Drug Products ◽  
Pharmaceutical Manufacturers

The article provides with different approaches to the assessment of pharmaceutical manufacturers’ innovation activity. The peculiarities of pharmaceutical industry product that can be characterized as innovative are taken into consideration. Special attention has been given to the pharmaceutical industry peculiarities originating from differentiation of original drug products and generics in the structure of pharmaceutical industry production. Based on these findings the classification of Russian pharmaceutical manufacturers in accordance with their innovation activity extent evaluated by their activity in clinical trials conducting was developed. The classification is based upon k-means clustering algorithm with 5 clusters specified.The small amount of manufacturers involved in clinical trials conducting and some optimistic insights about the original products share were concluded hereafter.

Clinical trials and the origins of pharmaceutical fraud: Parke, Davis & Company, virtue epistemology, and the history of the fundamental antagonism

2020 ◽  
Vol 58 (4) ◽  
pp. 533-558
Author(s):  
Joseph M. Gabriel ◽  
Bennett Holman
Keyword(s):  
Clinical Trials ◽  
Pharmaceutical Industry ◽  
Virtue Epistemology ◽  
Medical Science ◽  
Ethical Framework ◽  
Late Nineteenth Century ◽  
Laboratory Science ◽  
Epistemic Virtues ◽  
History Of ◽  
Origin Point

This paper describes one possible origin point for fraudulent behavior within the American pharmaceutical industry. We argue that during the late nineteenth century therapeutic reformers sought to promote both laboratory science and increasingly systematized forms of clinical experiment as a new basis for therapeutic knowledge. This process was intertwined with a transformation in the ethical framework in which medical science took place, one in which monopoly status was replaced by clinical utility as the primary arbiter of pharmaceutical legitimacy. This new framework fundamentally altered the set of epistemic virtues—a phrase we draw from the philosophical field of virtue epistemology—considered necessary to conduct reliable scientific inquiry regarding drugs. In doing so, it also made possible new forms of fraud in which newly emergent epistemic virtues were violated. To make this argument, we focus on the efforts of Francis E. Stewart and George S. Davis of Parke, Davis & Company. Therapeutic reformers within the pharmaceutical industry, such as Stewart and Davis, were an important part of the broader normative and epistemic transformation we describe in that they sought to promote laboratory science and systematized clinical trials toward the twin goals of improving pharmaceutical science and promoting their own commercial interests. Yet, as we suggest, Parke, Davis & Company also serves as an example of a company that violated the very norms that Stewart and Davis helped introduce. We thus seek to describe one possible origin point for the widespread fraudulent practices that now characterize the pharmaceutical industry. We also seek to describe an origin point for why we conceptualize such practices as fraudulent in the first place.

Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials

2013 ◽  
Vol 3 (2) ◽  
pp. 101-103 ◽  
Author(s):  
Paola Angelini ◽  
Kathryn Pritchard-Jones ◽  
Darren R Hargrave
Keyword(s):  
Clinical Trials ◽  
Pharmaceutical Industry ◽  
Pediatric Oncology ◽  
Oncology Clinical Trials

scholarly journals Sir Ralph Kohn. 9 December 1927—11 November 2016

2018 ◽  
Vol 65 ◽  
pp. 235-247
Author(s):  
Peter Collins
Keyword(s):  
Clinical Trials ◽  
Pharmaceutical Industry ◽  
Medical Science ◽  
Early Years ◽  
Related Services ◽  
Advanced Science ◽  
Science In Society

Ralph Kohn advanced medical science primarily through his pioneering development of independent and rigorous clinical trials and the provision of related services to the pharmaceutical industry. He also advanced science more generally through philanthropy, with a major science-in-society programme among a number of key initiatives that he facilitated. His contributions to science grew out of the sort of person he was. Gifted, certainly, in many different ways, and hardworking, ambitious, something of a perfectionist, keen to make the most of the opportunities that he encountered or created. Perhaps more important, however, he cared about other people, was willing to take the risks of being independent, maintained effective networks across many cultures, languages and disciplines, was passionate about both science and music (and many other things), and showed great generosity in his support and encouragement of causes and individuals. He was also fiercely proud and protective of his family, never forgetting how central family had been to his own survival through the traumas of his early years and, indeed, through the rest of his life.

Sign in / Sign up

Export Citation Format

Share Document